While significant progress has been seen in fields such as cardiovascular medicine and cancer in improving patient stratification and developing targeted drugs based on genetic findings, progress continues to lag for neuropsychiatric disorders where critical challenges include insufficient mechanistic insights and a lack of biomarkers that can be used to stratify patients within broad symptom-based diagnostic categories. On October 5-6, 2021, this virtual public workshop will bring together experts and key stakeholders to discuss new genetic and neuroscience technologies and explore how these discoveries can be used to advance the development targeted therapies and biomarkers for patients with neuropsychiatric disorders.